More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$3.90B
EPS
-0.2
P/E ratio
--
Price to sales
--
Dividend yield
--
Beta
2.740402
Previous close
$7.47
Today's open
$24.11
Day's range
$16.70 - $24.89
52 week range
$1.39 - $24.89
show more
CEO
Angelos M. Stergiou
Employees
13
Headquarters
New York, NY
Exchange
NASDAQ Capital Market
Shares outstanding
203859151
Issue type
Common Stock
Healthcare
Biotechnology & Life Sciences
SELLAS Life Sciences Announces Pricing of $150.0 Million Underwritten Public Offering
NEW YORK, Nov. 18, 2026 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced the pricing of its previously announced underwritten public offering of 11,538,462 shares of its common stock at a public offering price of $13.00 per share. All of the shares in the offering will be sold by SELLAS, with gross proceeds to SELLAS expected to be $150.0 million before deducting underwriting discounts and commissions and offering expenses. In addition, SELLAS has also granted the underwriters a 30-day option to purchase up to 1,730,769 additional shares of its common stock at the public offering price, less underwriting discounts and commissions. The offering is expected to close on November 20, 2026, subject to the satisfaction of customary closing conditions.
GlobeNewsWire • 8 hours ago

Sellas' cancer vaccine extends survival in blood cancer trial
Drug developer Sellas Life Sciences said on Tuesday its experimental vaccine for a type of blood cancer helped patients live significantly longer in a late-stage trial, sparking a record one-day surge in its shares.
Reuters • Nov 17, 2026

Another Cancer Vaccine Just Scored A Home Run; Shares Catapult 170%
Sellas Life Sciences catapulted early Tuesday after its experimental cancer vaccine cut the risk of death for leukemia patients.
Investors Business Daily • Nov 17, 2026

SELLAS Stock Triples on Cancer Vaccine Cutting Death Risk by 41% in Pivotal Leukemia Trial,
SELLAS Life Sciences Group Inc. (NASDAQ:SLS) skyrocketed to a 52-week high on Tuesday with a session volume of a massive 57.567 million compared to an average volume of 6.897 million, according to Benzinga Pro data.
Benzinga • Nov 17, 2026

SELLAS Life Sciences Group, Inc. (SLS) Discusses Positive Phase III REGAL Trial Results for Galinpepimut-S in Acute Myeloid Leukemia Prepared Remarks Transcript
SELLAS Life Sciences Group, Inc. ( SLS ) Discusses Positive Phase III REGAL Trial Results for Galinpepimut-S in Acute Myeloid Leukemia November 17, 2026 7:45 AM EST Company Participants Angelos Stergiou - Founder, President, CEO & Director Conference Call Participants John Fraunces - Lifesci Advisors, LLC Presentation Operator Greetings, and welcome to the SELLAS Life Sciences Group REGAL Phase III trial top line primary endpoint results webcast. [Operator Instructions] And as a reminder, this webcast is being recorded.
Seeking Alpha • Nov 17, 2026

SELLAS Life Sciences Announces Positive Pivotal Phase 3 REGAL Trial Data Showing Immunotherapeutic Cancer Vaccine, Galinpepimut-S (GPS), Demonstrated a Statistically Significant and Clinically Meaningful Improvement in Overall Survival in Patients with Acute Myeloid Leukemia
- REGAL trial met its primary endpoint with GPS demonstrating statistically significant and clinically meaningful reduction in risk of death by 41% with median overall survival of 24.0 months versus 14.7 months for best available treatment, and a hazard ratio of 0.59 (p=0.035) -
GlobeNewsWire • Nov 17, 2026

SELLAS Life Sciences Announces Proposed $150.0 Million Underwritten Public Offering
NEW YORK, Nov. 17, 2026 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that it has commenced an underwritten public offering of $150.0 million of shares of its common stock. SELLAS intends to grant the underwriters a 30-day option to purchase up to an additional $22.5 million of shares of its common stock under the same terms and conditions.
GlobeNewsWire • Nov 17, 2026

Sellas Life Sciences Stock Jumps on Trial Results Timeline
Sellas Life Sciences Group Inc (NASDAQ:SLS) stock is up 7% to trade at $8.59 after the biotech company announced that results from its closely watched leukemia trial are expected later this month.
Schaeffers Research • Nov 13, 2026

SELLAS Life Sciences Reports Third Quarter 2026 Financial Results and Provides Corporate Update
- Topline Primary Endpoint Results of the Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia Following the 80th Event to Report this Month - - 40 Patients Enrolled in Phase 2 Trial of SLS009 in Newly Diagnosed First-Line AML; Preliminary Topline Data Expected in Q4 2026 - - $134.7 Million in Cash and Cash Equivalents as of September 30, 2026 - NEW YORK, Nov. 12, 2026 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS'' or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today reported financial results for the third quarter ended September 30, 2026, and provided a corporate update. “We continue to execute across both of our clinical programs as we approach several important milestones,” said Angelos Stergiou, MD, ScD h.c.
GlobeNewsWire • Nov 12, 2026

SELLAS Life Sciences to Present Positive Phase 2 Data Demonstrating Encouraging Response and Survival Outcomes with SLS009 Combination in High-Risk AML at ASH 2026
− Company to present Phase 2 clinical data evaluating SLS009 (tambiciclib) in combination with azacitidine and venetoclax in patients who have previously failed venetoclax-based therapy − − Patients with relapsed/refractory monocytic AML achieved a 54% ORR with a median overall survival (mOS) of 5.8 months and patients with TP53-mutated AML achieved a 57% ORR and a mOS of 8.8 months, comparing favorably to historical outcomes in these adverse-risk settings of ~2.5 months − − Study showed that SLS009 (tambiciclib) combination was well-tolerated with no meaningful added toxicity − NEW YORK, Nov. 04, 2026 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that data from its completed Phase 2 study of SLS009 (tambiciclib) for the treatment of relapsed or refractory acute myeloid leukemia (r/r AML) will be presented at the 68th American Society of Hematology (ASH) Annual Meeting and Exposition, being held December 12–15, 2026 in New Orleans. This Phase 2 trial evaluated SLS009, a highly selective CDK9 inhibitor, in combination with azacitidine (AZA) and venetoclax (VEN) for the treatment of patients with r/r AML after prior VEN-based treatment.
GlobeNewsWire • Nov 4, 2026

¹ Disclosures

Open an M1 investment account to buy and sell SELLAS Life Sciences Group Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.